Amniotics AB (OSTO:AMNI) Cash Flow from Others : kr-6.62 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Amniotics AB Cash Flow from Others?

Amniotics AB's cash flow from others for the three months ended in Dec. 2023 was kr-5.71 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2023 was kr-6.62 Mil.

Amniotics AB Cash Flow from Others Historical Data

The historical data trend for Amniotics AB's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amniotics AB Cash Flow from Others Chart

Amniotics AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Others

0.06

-0.08

-1.46

Amniotics AB Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Cash Flow from Others	Get a 7-Day Free Trial										12.59	-0.03	-0.23	-0.68	-5.71

Amniotics AB Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-6.62 Mil.

Amniotics AB Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Amniotics AB's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.

Amniotics AB (OSTO:AMNI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amniotics AB (OSTO:AMNI) » Definitions » Cash Flow from Others

Comparable Companies

Traded in Other Exchanges

66J:Germany

Address

Scheelevagen 2, Lund, SWE, 223 63

Website

https://www.amniotics.com

Amniotics AB is a biopharma company focusing on mesenchymal stem cells from amniotic fluid. It provides a novel platform for the production of medically superior mesenchymal stem cells including ethical and medically sound bio-banking opportunities for the newborn.